BioPharma Resources

Drug Trial Radar · NCT03424005

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,132 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,132

Planned (sponsor's estimate)

Start

Mar 30, 2018

Primary completion

Sep 30, 2030

Study completion Sep 30, 2030

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Gilead Sciences; Pfizer
First posted
Feb 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven cohorts will be enrolled in parallel in this study: Cohort 1 will consist of programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line \[1L\] PD-L1+ cohort). Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line \[2L\] CIT-naïve cohort). Cohort 3, 5, 6 and 7 will consist of participants with locally advanced or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative disease with one or more PIK3CA mutations. Cohort 4 will consist of participants with locally advanced or metastatic HER2+ /HER2-low disease with one or more PIK3CA mutations who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort). In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). During Stage 2, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination, provided Stage 2 is open for enrollment and all eligibility criteria are met.

Conditions

  • Metastatic Breast Cancer

Interventions

  • CapecitabineDrug

    Capecitabine will be administered 1250 milligrams per square meter (mg/m\^2) orally twice daily on Days 1-14 of each 21-day cycle.

  • AtezolizumabDrug

    For Atezolizumab + SGN-LIV1A, Atezolizumab + Sacituzumab Govitecan, or Atezolizumab + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle. For Atezolizumab + Nab-Paclitaxel, Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Ipatasertib, or Atezolizumab + Nab-Paclitaxel + Tocilizumab arms: atezolizumab will be administered IV, 840 mg on Days 1 and 15 of each 28-day cycle.

  • IpatasertibDrug

    Ipatasertib will be administered by mouth 400 mg once a day, on Days 1-21 of each 28-day cycle.

  • SGN-LIV1ADrug

    SGN-LIV1A will be administered IV, 2.5 milligrams per kilogram (mg/kg) (maximum calculated dose 250 mg), on Day 1 of each 21-day cycle.

  • BevacizumabDrug

    Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28-day cycle.

  • Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug

    Gemcitabine will be administered by IV, 1000 mg/m\^2, along with carboplatin, by IV, on Days 1 and 8 of each 21-day cycle. Or Eribulin will be administered IV, 1.4 mg/m\^2 on Days 1 and 8 of each 21-day cycle.

  • SelicrelumabDrug

    Selicrelumab will be administered by subcutaneous (SC) injection, at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (Cycle = 28 days).

  • TocilizumabDrug

    Tocilizumab will be administered IV, 8 mg/kg on Day 1 of each 28-day cycle.

  • Nab-PaclitaxelDrug

    Nab-Paclitaxel will be administered IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.

  • Sacituzumab GovitecanDrug

    Sacituzumab govitecan will be administered by IV infusion, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.

  • AbemaciclibDrug

    Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each 28-day cycle.

  • FulvestrantDrug

    For Inavolisib + Abemaciclib + Fulvestrant, Inavolisib + Ribociclib (Dose #1) + Fulvestrant, Inavolisib + Ribociclib (Dose #2) + Fulvestrant, or Inavolisib + Atirmociclib + Fulvestrant arms: Fulvestrant 500 mg, administered as an IM injection on Days 1 and 15 of Cycle 1, followed by Day 1 of each 28-day cycle thereafter. For Empa + Inavolisib + Fulvestrant ± Palbociclib, or Metformin + Inavolisib + Fulvestrant ± Palbociclib arms: Fulvestrant 500 mg, administered as an IM injection on Day 1 and as per local prescribing guidelines thereafter.

  • Ribociclib (Dose #1)Drug

    Ribociclib tablets will be administered by mouth once daily.

  • Inavolisib (Dose #1)Drug

    Inavolisib tablets will be administered by mouth once daily.

  • Trastuzumab DeruxtecanDrug

    Trastuzumab Deruxtecan will be administered IV, 5.4 mg/kg on Day 1 of each 21-day cycle.

  • Ribociclib (Dose #2)Drug

    Ribociclib tablets will be administered by mouth once daily.

  • LetrozoleDrug

    Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each 28-day cycle.

  • Inavolisib (Dose #2)Drug

    Inavolisib tablets will be administered by mouth OD.

  • EmpagliflozinDrug

    Empagliflozin, administered orally, once daily (QD)

  • PalbociclibDrug

    For Empagliflozin + Inavolisib + Fulvestrant ± Palbociclib arm: Palbociclib 125 mg administered orally, QD in Cycle 1 followed by 125 mg on Days 1-21 of each cycle. For Metformin + Inavolisib + Fulvestrant ± Palbociclib arm: Palbociclib 125 mg administered orally, QD in Cycle 1, followed by 125 mg on Days 1-21 of each cycle (Cycle=28 days).

  • MetforminDrug

    Metf 1000 mg administered orally QD.

  • AtirmociclibDrug

    Atirmociclib administered orally, BID on Days 1-28 for each 28-day cycle.

  • GiredestrantDrug

    Giredestrant 30 mg will be administered by mouth once daily, on Days 1-28 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Baseline until disease progression or loss of clinical benefit (up to approximately 12 years)

Locations

55 sites in 9 countries. Site status is shown where the registry gives one.

  • City of Hope - Duarte

    Duarte, California · Recruiting

  • City of Hope

    Duarte, California · Completed

  • City of Hope - Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • University of California San Diego (UCSD) - Koman Family Outpatient Pavilion ? La Jolla

    La Jolla, California · Recruiting

  • University of California San Diego Medical Center

    La Jolla, California · Completed

  • UCLA Health 200 Medical Plaza

    Los Angeles, California · Recruiting

  • Stanford Cancer Institute

    Stanford, California · Withdrawn

  • Rocky Mountain Cancer Center - Longmont

    Longmont, Colorado · Completed

  • H. Lee Moffitt Cancer Center and Research Inst.

    Tampa, Florida · Completed

  • City of Hope® Cancer Center Chicago

    Zion, Illinois · Recruiting

  • Metro-Minnesota Community Oncology Research Consortium

    Saint Paul, Minnesota · Recruiting

  • Nebraska Cancer Specialists - Midwest Cancer Center - Legacy

    Omaha, Nebraska · Recruiting

  • Renown Regional Medical Center

    Reno, Nevada · Recruiting

  • Hackensack Univ Medical Center

    Hackensack, New Jersey · Withdrawn

  • Regional Cancer Care Associates, LLC

    Howell Township, New Jersey · Withdrawn

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Withdrawn

  • NYU Langone Medical Center

    New York, New York · Withdrawn

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Withdrawn

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Withdrawn

  • Tennessee Oncology - Chattanooga Oncology & Hematology Associates

    Chattanooga, Tennessee · Recruiting

  • The West Clinic

    Germantown, Tennessee · Recruiting

  • Tennessee Oncology PLLC

    Nashville, Tennessee · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Texas Oncology-Plano East

    Plano, Texas · Withdrawn

  • Peter MacCallum Cancer Centre-East Melbourne

    Melbourne, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital - Medical Oncology

    Murdoch, Western Australia, Australia · Recruiting

  • Centre Léon Bérard

    Lyon, France · Completed

  • Institut régional du Cancer Montpellier

    Montpellier, France · Withdrawn

  • Institut Universitaire du Cancer de Toulouse-Oncopole

    Toulouse, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Universitätsklinikum Erlangen

    Erlangen, Germany · Recruiting

  • Universitätsklinikum Essen

    Essen, Germany · Recruiting

  • Rambam Medical Center

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center

    Jerusalem, Israel · Recruiting

  • Hadassah University Medical Center

    Jerusalem, Israel · Recruiting

  • Rabin MC

    Petah Tikva, Israel · Recruiting

  • Sheba Medical Center

    Ramat Gan, Israel · Recruiting

  • Tel-Aviv Sourasky Medical Center

    Tel Aviv, Israel · Recruiting

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.